Galmed Pharmaceuticals (NASDAQ:GLMD) just reported results for the fourth quarter of 2023.
- Galmed Pharmaceuticals reported earnings per share of -98 cents. This was below the analyst estimate for EPS of -32 cents.
- The company did not report any revenue for the quarter.
InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.
